OncoMatch/Clinical Trials/NCT04118114
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
Is NCT04118114 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PRL3-zumab for gastric cancer.
Treatment: PRL3-zumab — This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy. Approximately 30 patients will be recruited with \~10 gastric cancers and \~10 hepatocellular carcinomas. Patients who have received at least 1 dose of PRL3-ZUMAB will be evaluable for toxicity and efficacy. PRL3-ZUMAB will be given IV every 2 weeks for up to 12 infusions in the absence of unmanageable toxicities or disease progression. Patients who are benefitting from the treatment may continue on PRL3-ZUMAB beyond 12 infusions with the agreement of the study drug provider. PRL3-ZUMAB at the RP2D in tumour types enriched for known PRL-3 expression for efficacy and tolerability will be evaluated. There will also be in depth molecular profiling of tissues in patients who have an objective response or prolonged disease stabilization to identify predictive/selection biomarkers as well as evaluation of the oncogenic signaling modulation and immunomodulation by PRL3-ZUMAB and its potential for future combination with other targeted therapies or immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Hepatocellular Carcinoma
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 x 10^9/L. Platelet count ≥ 75 x 10^9/L. Hemoglobin ≥ 9 g/dL. Prothrombin time and activated partial thromboplastin time ≤ 1.5 x ULN.
Kidney function
Creatinine < 1.5x ULN
Liver function
Total bilirubin ≤ 1.5x ULN. AST/ALT ≤ 3 x ULN (≤ 5x ULN in the presence of liver mets). For HCC: Child Pugh score of ≤ B7.
Adequate organ and hematological function as evidenced by the following laboratory studies within 10 days of 1st treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify